Associations - ER mutation

ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials	palbociclib Sensitive: B - Late Trials
ER mutation ER mutation	Breast Cancer Breast Cancer	ER mutation ER mutation	Breast Cancer Breast Cancer	palbociclib Resistant: B - Late Trials	palbociclib Resistant: B - Late Trials
ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	exemestane Resistant: B - Late Trials	exemestane Resistant: B - Late Trials
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials	fulvestrant Sensitive: B - Late Trials
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	exemestane Resistant: B - Late Trials	exemestane Resistant: B - Late Trials
ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials	fulvestrant Sensitive: B - Late Trials
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	Aromatase inhibitor + palbociclib Resistant: B - Late Trials	Aromatase inhibitor + palbociclib Resistant: B - Late Trials
ER mutation ER mutation	Breast Cancer Breast Cancer	ER mutation ER mutation	Breast Cancer Breast Cancer	fulvestrant Sensitive: C2 – Inclusion Criteria	fulvestrant Sensitive: C2 – Inclusion Criteria
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	GDC-9545 Sensitive: C2 – Inclusion Criteria	GDC-9545 Sensitive: C2 – Inclusion Criteria
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials	palbociclib + PF-05212384 Sensitive: C3 – Early Trials
ER mutation ER mutation	Breast Cancer Breast Cancer	ER mutation ER mutation	Breast Cancer Breast Cancer	venetoclax Sensitive: C3 – Early Trials	venetoclax Sensitive: C3 – Early Trials
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	enobosarm Sensitive: C3 – Early Trials	enobosarm Sensitive: C3 – Early Trials
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	SAR439859 Sensitive: C3 – Early Trials	SAR439859 Sensitive: C3 – Early Trials
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK6 inhibitor Resistant: C3 – Early Trials	CDK6 inhibitor Resistant: C3 – Early Trials
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK4 inhibitor Resistant: C3 – Early Trials	CDK4 inhibitor Resistant: C3 – Early Trials
ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	alpelisib Resistant: C3 – Early Trials	alpelisib Resistant: C3 – Early Trials
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	RAD1901 Sensitive: C3 – Early Trials	RAD1901 Sensitive: C3 – Early Trials
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	bevacizumab + paclitaxel Sensitive: C3 – Early Trials	bevacizumab + paclitaxel Sensitive: C3 – Early Trials
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	G1T48 Sensitive: C4 – Case Studies	G1T48 Sensitive: C4 – Case Studies
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	RAD1901 Sensitive: D – Preclinical	RAD1901 Sensitive: D – Preclinical